- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05299606
POWER Study (Prospective Transbronchial Microwave + Robotic-Assisted Bronchoscopy)
A Prospective Multicenter Study of Transbronchial Microwave Ablation Using Robotic-Assisted Bronchoscopy in Subjects With Oligometastatic Tumors in the Lung
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Erin Meyers, MBA
- Phone Number: 937-681-0322
- Email: eprifog1@its.jnj.com
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada
- Not yet recruiting
- University of Toronto
-
-
Quebec
-
Montreal, Quebec, Canada
- Recruiting
- Centre Hospitalier de l'Université de Montréal
-
-
-
-
-
Sha Tin, Hong Kong
- Recruiting
- Prince of Wales Hospital
-
-
-
-
California
-
Stanford, California, United States, 94305
- Recruiting
- Stanford University School of Medicine
-
-
Connecticut
-
Farmington, Connecticut, United States, 06030
- Recruiting
- UConn Health
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55407
- Recruiting
- Minnesota Lung Center
-
-
North Carolina
-
Pinehurst, North Carolina, United States, 28374
- Recruiting
- FirstHealth Moore Regional Hospital
-
-
Ohio
-
Cleveland, Ohio, United States, 44195
- Recruiting
- Cleveland Clinic
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Recruiting
- University of Pennsylvania
-
-
Texas
-
Houston, Texas, United States, 77030
- Recruiting
- MD Anderson
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
INCLUSION CRITERIA:
- Signed informed consent.
- Subjects greater or equal to 22 years old.
- Performance status 0-2 (Eastern Cooperative Oncology Group classification (ECOG).
- Willing to fulfill all follow-up visit requirements.
- Subjects with at least one oligometastatic lung tumor where the primary tumor is controlled (in the opinion of the investigator or treating oncologist).
- Oligometastatic lung tumor(s) planned to be ablated in the outer two-thirds of the lung and not closer than 1cm to the pleura.
EXCLUSION CRITERIA:
- Pregnant or breastfeeding.
- Subjects with thoracic implantable devices, including pacemakers or other electronic implants.
- Chronic, continuous ventilator support, which uses bi-level positive airway pressure (PAP) to improve lung function for severe conditions. (However, intermittent PAP, for non-pulmonary conditions, such as sleep apnea, is permitted).
- Prior pneumonectomy.
- Severe bronchiectasis (with FEV1 <30%) or disease deemed to be too severe in the opinion of the investigator.
- Platelet count ≤ 50,000/mm3.
- Subjects with uncorrectable coagulopathy at time of screening.
- Subjects medically unable to stop anti-platelet agents (e.g., aspirin, clopidogrel, prasugrel, ticagrelor) at least 5 days prior to the procedure through 48-72 hours after the procedure.
- Subjects medically unable to stop warfarin at least 3-5 days prior to the ablation procedure, or until INR < 1.5, through 48-72 hours after the procedure. On the day of the procedure, subjects with an INR > 1.5 cannot have the procedure completed that day but may be rescheduled or postponed.
- Subjects medically unable to stop anticoagulants (e.g., rivaroxaban, apixaban, dabigatran, endoxaban) at least 3 days prior to the ablation procedure through 48-72 hours after the procedure.
- Expected survival less than 6 months in the opinion of the investigator and/or treating oncologist.
- Subjects with known or suspected brain metastases.
- Subject has had any radiation (i.e., SBRT or EBRT) to the intended ablation zone.
- Endobronchial tumors proximal to and including the segmental airways.
- Lung ablation, surgical resection therapy, radiotherapy, or any other treating procedure within 30 days prior to the planned study ablation procedure or those who plan to receive a lung ablation, surgical resection, or radiation therapy on the ablated lung side before completing the primary endpoint assessment (30 days post-ablation).
- Systemic therapy (e.g., chemotherapy, targeted drug therapy, or immunotherapy) within 14 days prior to the planned study ablation procedure or those who plan to receive systemic therapy before completing the primary endpoint assessment (30 days post-ablation).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Transbronchial Microwave Ablation
Transbronchial microwave ablation will be performed using the NEUWAVE FLEX Microwave Ablation System and Accessories on oligometastatic tumors in the peripheral lung, guided by the Auris MONARCH Platform for visualization and access while using cone beam CT (computed tomography) to confirm probe tip placement and final ablation zone.
|
Transbronchial microwave ablation will be performed using the NEUWAVE FLEX Microwave Ablation System and Accessories on oligometastatic tumors in the peripheral lung, guided by the Auris MONARCH Platform for visualization and access while using cone beam CT (computed tomography) to confirm probe tip placement and final ablation zone.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Technique Efficacy
Time Frame: 30 days (-7 to +14 days) post-ablation
|
Ablation of the target tumor(s) with the ablation zone completely overlapping or encompassing the entire target tumor(s) using CT imaging.
|
30 days (-7 to +14 days) post-ablation
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Technical Success
Time Frame: Immediately post-ablation (day 0)
|
A complete tumor ablation with a surrounding minimal margin as assessed by cone beam CT imaging.
|
Immediately post-ablation (day 0)
|
Navigational Success
Time Frame: During navigation (day 0)
|
Successful navigation to the targeted peripheral lung tumor(s) as confirmed using cone beam CT.
|
During navigation (day 0)
|
Local Tumor Progression
Time Frame: 12-month visit
|
Recurrence of the originally ablated target tumor(s) within or abutting the ablation zone using the 30-day post-ablation imaging as the baseline.
|
12-month visit
|
Local Tumor Progression Free Survival
Time Frame: 12-month visit
|
Time from the ablation until local tumor(s) progression or death, whichever occurs first.
|
12-month visit
|
Progression Free Survival
Time Frame: 12-month visit
|
Time from the original ablation until tumor(s) progression or death, whichever occurs first (includes local, regional, or distant progression).
|
12-month visit
|
Disease (cancer) Specific Survival
Time Frame: 12-month visit
|
Time from the original ablation until death from the treated primary malignancy.
|
12-month visit
|
Overall Survival
Time Frame: 12-month visit
|
Time from the original ablation until subject death (includes death from any cause).
|
12-month visit
|
Repeat Ablation Efficacy Rate
Time Frame: 12-month visit
|
Rate of original tumors that have been re-ablated successfully (i.e., Technical Success of tumors that have been re-ablated out of all original tumors that have been re-ablated).
|
12-month visit
|
Change in Pulmonary Function Tests (Spirometry I)
Time Frame: 12-month visit
|
Change in all available (i.e., what is site standard-of-care) spirometry tests from pre-ablation baseline values to values at 3-months, 6-months, and 12-months post-ablation. Spirometry tests are non-invasive and measure how much air one can breathe in and out of one's lungs, as well as how easily and fast one can the blow the air out of one's lungs. These tests include FVC (forced vital capacity, % of predicted), FEV1 (forced expiratory volume, % of predicted), FEV1/FVC (% ratio), and FEV 25-75 (average flow at which 25% has been exhaled through the point which 75% has been exhaled), all of which are expressed as a percentage. |
12-month visit
|
Change in Pulmonary Function Tests (Spirometry II)
Time Frame: 12-month visit
|
Change in peak expiratory flow and maximum ventilation volume spirometry tests from pre-ablation baseline values to values at 3-months, 6-months, and 12-months post-ablation. Peak Expiratory Flow is the maximal rate that one can exhale during a short maximal expiratory effort after a full inspiration and Maximum Ventilation Volume is the maximum minute volume of ventilation that one can maintain for 12-15 seconds. Both tests are expressed as L/min. |
12-month visit
|
Change in Pulmonary Function Tests (Diffusion Capacity)
Time Frame: 12-month visit
|
Change in diffusion capacity from the pre-ablation baseline value to values at 3-months, 6-months, and 12-months post-ablation. The diffusion capacity test measures the volume of carbon monoxide transferred from the lung to blood and is measured in ml/min/mmHg and put into a percentage (% of predicted). |
12-month visit
|
Change in Pulmonary Function Tests (Lung Volume)
Time Frame: 12-month visit
|
Change in lung volume from the pre-ablation baseline values to values at 3-months, 6-months, and 12-months post-ablation. The lung volume tests include plethysmographic TLC (total lung capacity), plethysmographic FRC (functional residual capacity), plethysmographic RV (residual volume), gas dilution TLC, gas dilution FRC, and gas dilution RV. A plethysmograph measures changes in volume within an organ and a gas dilution test may determine lung volumes that cannot be determined from simple spirometry. All assessments are collected in liters (L) and put into a percentage (% of predicted). |
12-month visit
|
Change in EORTC QLQ-C30
Time Frame: 12-month visit
|
Change in quality of life scores per the validated EORTC (European Organization for Research and Treatment of Cancer) QLQ-C30 questionnaire from pre-ablation baseline scores to scores at 3-months, 6-months, and 12-months post-ablation.
The questionnaire asks cancer patients to choose a response that most closely describes them for 30 questions on a scale from 1-4 (1 being 'not at all', 2 being 'a little', 3 being 'quite a bit' and 4 being 'very much).
The 30 questions are separated into sections for 'general quality of life', 'during the past week', and 'overall health and quality of life'.
|
12-month visit
|
Change in EORTC QLQ-LC13
Time Frame: 12-month visit
|
Change in quality of life scores per the validated EORTC (European Organization for Research and Treatment of Cancer) QLQ-LC13 questionnaire from pre-ablation baseline scores to scores at 3-months, 6-months, and 12-months post-ablation.
The questionnaire asks lung-cancer patients to choose a response that most closely describes them for 13 questions on a scale from 1-4 (1 being 'not at all', 2 being 'a little', 3 being 'quite a bit' and 4 being 'very much).
The 13 questions are all about symptoms and problems experienced during the past week.
|
12-month visit
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NEU_2020_03
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lung Neoplasms
-
UNC Lineberger Comprehensive Cancer CenterSivan Innovation Ltd.CompletedLung Cancer | Neoplasms, Lung | Pulmonary Neoplasms | Neoplasms, Pulmonary | Pulmonary Cancer | Cancer of LungUnited States
-
Baptist Health South FloridaWithdrawnLung Cancer | Lung TumorUnited States
-
Oliver JonasMassachusetts General HospitalCompletedLung Cancer | Lung TumorUnited States
-
C. R. BardCompleted
-
Portsmouth Hospitals NHS TrustCompletedLung Cancer | Interstitial Lung DiseaseUnited Kingdom
-
Azienda Sanitaria-Universitaria Integrata di UdineRecruitingLung Diseases | Lung Cancer | Lung Adenocarcinoma | Lung Transplant Rejection | Lung; Node | Lung TBItaly
-
Point TherapeuticsTerminatedCarcinoma, Non-Small-Cell Lung | Lung Cancer | Neoplasms, Lung | Neoplasms, PulmonaryUnited States
-
University of UtahRecruitingLung Cancer | Lung Neoplasms/DiagnosisUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)CompletedLung Carcinoma | Lung Neoplasm | Malignant Lung NeoplasmUnited States
-
Keimyung University Dongsan Medical CenterCompletedLung Cancer | Lung Diseases, Interstitial
Clinical Trials on Transbronchial Microwave Ablation
-
Wenjun WuFirst Affiliated Hospital of Wenzhou Medical UniversityUnknown
-
Assiut UniversityNot yet recruitingThyroid Nodule (Benign)
-
Qianfoshan HospitalShandong Provincial HospitalNot yet recruitingAdvanced Non Small Cell Lung CancerChina
-
Zagazig UniversityCompletedHepatocellular Carcinoma
-
The First Affiliated Hospital with Nanjing Medical...Recruiting
-
Karolinska InstitutetRecruitingPortal Hypertension | Splenomegaly; Congestive, Chronic | Panhematopenia; SplenicSweden
-
The First People's Hospital of ChangzhouCompletedColorectal Cancer
-
Chinese University of Hong KongThe Hong Kong Society of GastroenterologyCompletedHepatocellular CarcinomaHong Kong
-
University Medical Center GroningenNot yet recruitingBreast Cancer Stage I